In utero and postnatal exposure to antiretrovirals among hiv-exposed but uninfected children in the united states

摘要: An increasing number of antiretroviral agents (ARVs) are approved for use, but their use during pregnancy in the United States has not been completely described. We used data from Pediatric HIV/AIDS Cohort Study (PHACS) Surveillance Monitoring ART Toxicities (SMARTT) study, a States-based prospective cohort study HIV-exposed uninfected children, to assess temporal trends and maternal characteristics associated with ARVs pregnancy. The proportion children exposed utero was calculated over time. A multivariable logistic regression model estimate associations highly active therapy (HAART) studied 1768 born between 1995 2009 enrolled SMARTT. Prenatal HAART exposure increased 19% 1997 88% 2009. Of 2009, 99% had prenatal NRTIs (including zidovudine, 73%; lamivudine, 72%; tenofovir, 39%; emtricitabine, 37%). Exposure protease inhibitors 15% 86% while non-nucleoside reverse transcriptase (NNRTIs) declined 33% 2003 11% Higher HIV RNA viral load (VL) concentration, lower CD4 count, earlier timing first or VL measurement were odds exposure. is universal. As ARV continues evolve, follow-up needed long-term effects exposures.